Gontivimab Biosimilar - Research Grade

Human

RSV

>1mg/ml

VH - VH - VH

CHO Cells

Motavizumab Biosimilar - Research Grade (ICH5169), Clesrovimab Biosimilar - Research Grade (ICH5441), Felvizumab Biosimilar - Research Grade (ICH5546), Nirsevimab Biosimilar - Research Grade (ICH5712), Suptavumab Biosimilar - Research Grade (ICH5887)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This is a research-grade biosimilar of gontivimab (originator research code ALX-0171), supplied by ichor.bio as an unconjugated, non-therapeutic analog intended for research use only. Gontivimab is a trivalent single-domain antibody (nanobody) construct built from three linked VHH/VH domains, reflected in the VH-VH-VH format on this product, and it is directed against the respiratory syncytial virus (RSV) fusion (F) glycoprotein. This reagent reproduces the target-binding characteristics of the originator molecule and is intended as a benchmark and control tool for in-vitro and functional RSV research, not for clinical or therapeutic use. It is manufactured to a research-grade endotoxin specification (typically under 1 EU/mg), and is available in bulk milligram-to-gram quantities for assay development, comparability studies, and neutralisation work. Because it is an anti-viral-antigen binder rather than a host-target antibody, it is used chiefly to interrogate RSV F engagement and virus neutralisation rather than to modulate host immunity. It carries no therapeutic claims and should be handled as a laboratory reagent. Respiratory syncytial virus (RSV) is an enveloped negative-sense RNA virus and a leading cause of lower respiratory tract infection in infants, older adults, and immunocompromised patients. Its surface fusion (F) glycoprotein mediates fusion of the viral and host cell membranes and is a principal target of neutralising antibodies because it is highly conserved across RSV-A and RSV-B subgroups. F transitions from a metastable prefusion conformation to a stable postfusion form; the prefusion state displays the most potent neutralising epitopes. Gontivimab is a trivalent nanobody that binds antigenic site II on F, an epitope that overlaps the region recognised by palivizumab, and its multivalent format supports high-avidity engagement and virus neutralisation. Its small single-domain architecture allows access to conformational epitopes and was explored for direct pulmonary delivery. As a target, RSV F is central to neutralisation assays, epitope-mapping, and antiviral benchmarking.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Gontivimab biosimilar available in bulk or gram quantities?

A: Yes — the Gontivimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Gontivimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Gontivimab biosimilar bind?

A: It is an unconjugated, non-therapeutic analog of Gontivimab that recognises RSV.